Irvine of Allergan, Inc. will be giving $6.25 million to Asterand, an eye research company under an exclusive license agreement for selective compounds. These compounds arise from Asterand’s R99 development programme and are effective in reducing intra-ocular pressure. Allergan is planning to launch these compounds in market, once through with clinical development. Along with this amount, Asterand will be receiving other benefits such as payments for sales milestone, leading to a total of $56 million, excluding royalties.